Reuters
29 May 2026, 16:44 UTC · 2h ago
Source · https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-mannkinds-inhaled-insulin-children-2026-05-29/
Read source
Search tags
Story key points
1 claims · impact-rated
The FDA has approved the expanded use of MannKind's inhaled rapid-acting insulin for patients under 18 years of age. — Expanding the addressable patient population to include children typically drives revenue growth and increases the drug's market penetration.
+0.60Ticker attribution
Model heads
FDA approval for expanded use of its inhaled insulin in children provides a significant growth opportunity.
No ticker relationship head found.
Impact vectors
6 dimensions · 9 clusters
Continue reading
6 related stories
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Zacks Investment Research
1h ago
